Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?"
Apr 23, 2013, 06:00 ET
HERZLIYA-PITUACH, Israel, April 23, 2013 /PRNewswire/ -- Immune Pharmaceuticals Ltd. ("Immune"), a privately held Israeli company, announced today that the company's CEO Daniel Teper is the moderator of this morning's BIO International Convention breakout session "Can Israel Become the Next BioTech Startup Nation?" The panel, which will take place from 9:00 am – 9:45 am CT today at the conference in Chicago, IL, USA, will bring together life science thought leaders to discuss high-tech innovation and biotech areas of opportunity. Speakers at today's session include:
Ora Dar, Head of Life Sciences Office of the Chief Science at Israeli Ministry of Industry Trade and Labor
Nissim Darvish, M.D., Ph.D., Senior Managing Director at Orbimed Advisors LLC
Nadav Kidron,CEO, Oramed Pharmaceuticals Inc.
Yaacov Michlin CEO, Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem
About the Panel (Building: S101A; International Market Briefings Track)
Israel has become a model for high tech entrepreneurship. A country of 8 million people, Israel is home to a vibrant academic biomedical research sector, a global pharmaceutical company and several public biotech companies. Yet, the success of Israel's biotech sector pales in comparison to its high-tech industry. What can be learned from the Israeli Hi-tech Innovation and Entrepreneurship model and how can it be applied to biotech? Which regional partnerships can best leverage Israel's potential? What is the optimal positioning for Israeli Biotech to encourage biopharma companies and investors to step up their involvement? Complete panel information can be found here.
About Immune Pharmaceuticals Ltd.
Immune Pharmaceuticals Ltd. is an Israel and U.S.-based biopharmaceutical company focused on the treatment of inflammatory diseases and cancer. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from Cambridge Antibody Technology Limited, now part of MedImmune, the global biologics research and development arm of AstraZeneca. Additionally, Immune has licensed from Yissum, the technology transfer company of the Hebrew University of Jerusalem, the injectable applications of the antibody nanoparticle conjugate technology (NanomAbs®). For more information, visit www.immunepharmaceuticals.com.
SOURCE Immune Pharmaceuticals Ltd.
Share this article